Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Investing Activities (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Cash from Investing Activities for 6 consecutive years, with -$11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 2033.33% to -$11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$61.5 million, a 104.16% decrease, with the full-year FY2025 number at -$61.5 million, down 104.16% from a year prior.
  • Cash from Investing Activities was -$11.1 million for Q4 2025 at GeneDx Holdings, down from -$4.7 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $843000.0 in Q1 2024 to a low of -$130.3 million in Q2 2022.
  • A 5-year average of -$14.9 million and a median of -$4.9 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 2807.77% in 2022, then skyrocketed 282.47% in 2024.
  • GeneDx Holdings' Cash from Investing Activities stood at -$7.7 million in 2021, then surged by 63.11% to -$2.8 million in 2022, then tumbled by 71.39% to -$4.9 million in 2023, then soared by 89.33% to -$519000.0 in 2024, then crashed by 2033.33% to -$11.1 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Cash from Investing Activities are -$11.1 million (Q4 2025), -$4.7 million (Q3 2025), and -$36.4 million (Q2 2025).